

# Yumi Aoki Msn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3675974/publications.pdf>

Version: 2024-02-01

10  
papers

109  
citations

1478505

6  
h-index

1474206

9  
g-index

10  
all docs

10  
docs citations

10  
times ranked

106  
citing authors

#	ARTICLE	IF	CITATIONS
1	Shared decision making for adults with severe mental illness: A concept analysis. <i>Japan Journal of Nursing Science</i> , 2020, 17, e12365.	1.3	23
2	Efficacy and safety of bright light therapy for manic and depressive symptoms in patients with bipolar disorder: A systematic review and meta-analysis. <i>Psychiatry and Clinical Neurosciences</i> , 2020, 74, 247-256.	1.8	20
3	Seven-day shared decision making for outpatients with first episode of mood disorders among university students: A randomized controlled trial. <i>Psychiatry Research</i> , 2019, 281, 112531.	3.3	17
4	Does cognitive behavioral therapy for anxiety disorders assist the discontinuation of benzodiazepines among patients with anxiety disorders? A systematic review and meta-analysis. <i>Psychiatry and Clinical Neurosciences</i> , 2021, 75, 119-127.	1.8	11
5	The experiences of receiving a diagnosis of attention deficit hyperactivity disorder during adulthood in Japan: a qualitative study. <i>BMC Psychiatry</i> , 2020, 20, 373.	2.6	10
6	Psychiatric outpatients' experiences with shared decision-making: a qualitative descriptive study. <i>Journal of Communication in Healthcare</i> , 2019, 12, 102-111.	1.5	8
7	Development and acceptability of a decision aid for chronic insomnia considering discontinuation of benzodiazepine hypnotics. <i>Neuropsychopharmacology Reports</i> , 2022, 42, 10-20.	2.3	8
8	Development and field testing of a decision aid to facilitate shared decision making for adults newly diagnosed with attention-deficit hyperactivity disorder. <i>Health Expectations</i> , 2022, 25, 366-373.	2.6	6
9	Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission. <i>Neuropsychopharmacology Reports</i> , 2022, 42, 306-314.	2.3	6
10	Response to "Efficacy and safety of bright light therapy for bipolar depression". <i>Psychiatry and Clinical Neurosciences</i> , 2020, 74, 410-411.	1.8	0